GRACEcast offentlig
[search 0]
Mer
Download the App!
show episodes
 
Loading …
show series
 
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.Av cancerGRACE - H. Jack West, MD
  continue reading
 
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.Av cancerGRACE - H. Jack West, MD
  continue reading
 
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.Av cancerGRACE - H. Jack West, MD
  continue reading
 
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.Av cancerGRACE - H. Jack West, MD
  continue reading
 
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.Av cancerGRACE - H. Jack West, MD
  continue reading
 
Loading …

Hurtigreferanseguide

Copyright 2023 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett